NCT03365947: A trial that was reported late by Arrowhead Pharmaceuticals
This trial has reported, although it was 354 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03365947 |
|---|---|
| Title | A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 27, 2018 |
| Completion date | April 23, 2020 |
| Required reporting date | April 23, 2023, midnight |
| Actual reporting date | April 11, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 354 |